Status: Recruiting
Trastuzumab, Bevacizumab with Paclitaxel for HER2-positive Gastric Cancer in a Second-line Therapy
This is a multicenter, open-label, prospective, phase 2 study of trastuzumab, bevacizumab, and paclitaxel as second-line treatment for patients with HER2-positive advanced gastric cancer who had progressed on first-line chemotherapy including trastuzumab or anti-HER2 agents.
Participants needed: 47
Trial details
Phase: Phase 1, Phase 2Biological sex: AllType: InterventionalSponsor: Kangbuk Samsung HospitalUpdated: Nov 26, 2024Locations: 1
Eligibility criteria
HER2-positive advanced gastric cancer [+10]
Patients who have received chemotherapy, radiation therapy, immunotherapy or tar... [+6]